Related Experiment Video
Updated: May 15, 2025
09:34
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
8.9K
Advances in Nanostructured Lipid Carriers for Colorectal Cancer Treatment: A Comprehensive Review
Riya Patel1,2, Shailvi Shah3, Sheetal Acharya1
1L J Institute of Pharmacy, L J University, LJ Campus, Near Sarkhej-Sanand Circle, Off. S.G. Road, Ahmedabad-382 210.
Current Drug Delivery
|April 10, 2025
Summary
This study explores nanostructured lipid carriers (NLCs) to enhance colorectal cancer treatment by improving drug delivery and reducing side effects. Optimized NLCs offer targeted therapy with controlled administration for better patient outcomes.
Area of Science:
- Pharmaceutical Sciences
- Nanotechnology
- Oncology
Background:
- Colorectal cancer is a leading global malignancy.
- Current treatments face limitations in efficacy and side effects.
- Nanocarriers offer potential for improved drug delivery.
Purpose of the Study:
- To investigate nanostructured lipid carriers (NLCs) for enhanced colorectal cancer drug delivery.
- To overcome limitations of conventional chemotherapy.
- To achieve site-specific delivery and controlled drug release.
Main Methods:
- Literature review and analysis of nanocarrier research.
- Focus on optimization and characterization of NLCs.
- Evaluation of particle size, zeta potential, morphology, and biological compatibility.
Main Results:
- Optimal NLC particle size ranges from 10-200 nanometers.
- Ideal zeta potential is between -30 mV and +30 mV.
- Uniform spherical morphology and biological compatibility are key for optimal formulations.
Conclusions:
- NLCs show promise for improving colorectal cancer treatment efficacy.
- Optimized NLCs can enable targeted drug delivery and reduce systemic toxicity.
- Further research into nanocarrier development is crucial for advancing cancer therapy.
